The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
Olivia Pagani
Research Funding - Ipsen; Pfizer
Meredith M. Regan
No relevant relationships to disclose
Barbara Walley
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
Marco Colleoni
No relevant relationships to disclose
Istvan Lang
No relevant relationships to disclose
Henry Leonidas Gomez
No relevant relationships to disclose
Carlo Tondini
No relevant relationships to disclose
Harold J. Burstein
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose
Eva Ciruelos
No relevant relationships to disclose
Vered Stearns
Research Funding - Novartis; Pfizer
Herve R. Bonnefoi
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
Charles E. Geyer
No relevant relationships to disclose
Manuela Rabaglio-Poretti
No relevant relationships to disclose
Alan S. Coates
No relevant relationships to disclose
Richard D. Gelber
No relevant relationships to disclose
Aron Goldhirsch
No relevant relationships to disclose
Prudence A. Francis
No relevant relationships to disclose